Aerosol medications

Respiratory Care Clinics of North America

Volumn 8, Issue 2, 2002, Pages 309-334

  Kondili, Eumorfia ^a   Georgopoulos, Dimitris ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMINOGLYCOSIDE; AMPHOTERICIN B; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; ARTIFICIAL LUNG SURFACTANT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG; FENOTEROL; FORMOTEROL; GENTAMICIN; HELIUM; IMMUNOMODULATING AGENT; IPRATROPIUM BROMIDE; MUCOLYTIC AGENT; NITRIC OXIDE; OXITROPIUM BROMIDE; PENTAMIDINE; POLYMYXIN; PROSTACYCLIN; PROSTAGLANDIN E2; RIBAVIRIN; SALBUTAMOL; SALMETEROL; TERBUTALINE; TOBRAMYCIN; UNINDEXED DRUG; VASOACTIVE AGENT;

AEROSOL; AIRWAY RESISTANCE; ARTIFICIAL VENTILATION; ASTHMA; BRONCHODILATING ACTIVITY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; IMMUNOMODULATION; INHALATIONAL DRUG ADMINISTRATION; METHODOLOGY; NEBULIZER; PATIENT CARE; PHYSIOLOGY; REVIEW; SIDE EFFECT;

ADMINISTRATION, INHALATION; AEROSOLS; AIRWAY RESISTANCE; HUMANS; NEBULIZERS AND VAPORIZERS; PHARMACEUTICAL PREPARATIONS; RESPIRATION, ARTIFICIAL;

EID: 0036045618     PISSN: 10785337     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1078-5337(02)00011-4     Document Type: Article

References (183)

1. Aerosol therapy in mechanically ventilated patients: Recent advances and new techniques
2. Drug use in a trauma intensive care unit
3. Comparison of inhaled and intravenous terbutaline in acute severe asthma
4. Nebulized versus intravenous albuterol in hypercapnic acute asthma: Multicenter, double blind, randomised study
5. Fatal myocardial infraction during continuous in infusion of intravenous isoprotenerol during therapy of asthma
6. Continuous intravenous terbutaline infusions for adult patients with status asthmaticus
7. Bronchodilator delivery with metered-dose inhalers in mechanically ventilated patients
8. Inhaled bronchodilator therapy in mechanically ventilated patients
9. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS)
10. Ventilatory strategies in adult patients with status asthmaticus
11. Ventilatory strategies in acute exacerbations of chronic obstructive pulmonary disease
12. Mechanical ventilation. ACCP consensus conference
13. Disposable jet nebulizers: How reliable are they?
14. Substitution of metered-dose inhalers for hand nebulizers: Success and cost-saving in a large acute care hospital
15. An outbreak of Burkholderia (formerly Pseudomonas) cepacia respiratory track colonization and infection associated with nebulized albuterol therapy
16. Aerosol bronchodilator delivery methods: Relative impact on pulmonary function and cost of respiratory care
17. Continuous in-line nebulizers complicate pressure support ventilation
18. Aerosol bronchodilator delivery during mechanical ventilation nebulizer or inhaler?
19. Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients
20. Dose-response to bronchodilator delivered by metered dose inhaler in ventilator-support patients
21. Bronchodilator delivery by metered-dose inhaler in ventilator support patients
22. Bronchodilators in patients with obstructive pulmonary disease on mechanical ventilation: Utilisation of metered-dose inhalers
23. Bronchodilator delivery with metered-dose inhaler during mechanical ventilation
24. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: Influence of tidal volume
25. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: Influence of end-inspiratory pause
26. Bronchodilator delivery by metered-dose inhaler in mechanically ventilated COPD patients: Influence of flow pattern
27. Effect of inspiratory flow rate on beta2-agonists induced bronchodilation in mechanically ventilated COPD patients
28. Inhaled fenoterol-ipratropium bromide in mechanically ventilated patients with chronic obstructive pulmonary disease
29. Deposition of aerosol from metered-dose inhaler during mechanical ventilation: An in vitro model
30. Treatment of bronchospasm by meter-dose inhaler albuterol in mechanically ventilated patients
31. Duration of salbutamol-induced bronchodilation delivered by meter-dose inhaler in mechanically ventilated patients with chronic obstructive pulmonary disease
32. Bronchodilator therapy with metered-dose inhaler and spacer versus nebulizer in mechanically ventilated patients: Comparison of magnitude and duration of response
33. Serum albuterol levels in mechanically ventilated patients and healthy subjects after metered-dose inhaler administration
34. Beta-adrenergic agonists increase lung liquid clearance in anesthetized sheep
35. Effects of terbutaline on sodium transport in isolated perfused rat lung
36. Impact of beta-adrenergic agonists on Na channel and Na-K ATPase expression in alveolar type II cells
37. Sodium-independent modulation of Na-K ATPase activity by beta-adrenergic agonist in alveolar type II cells
38. Alveolar epithelial fluid transport can be simultaneously upregulated by both KGF and beta-agonists therapy
39. Alveolar epithelial fluid clearance persists in the presence of moderate left atrial hypertension in sheep
40. B- Adrenergic agonist therapy accelerates the resolution of hydrostatic pulmonary edema in sheep and rats
41. Terbutaline stimulates alveolar fluid resorption in hyperoxic lung injury
42. Beta-adrenergic agonist stimulated alveolar fluid clearance ex vivo human and rats
43. Alveolar fluid clearance in resected human lung
44. Isoprotenerol improves ability of lung to clear edema in rats exposed to hyperoxia
45. B-Adrenergic stimulation restores rat lung ability to clear edema in ventilatory-associated lung injury
46. Alveolar epithelial fluid transport and the resolution of clinically, severe hydrostatic pulmonary edema
47. Treatment of adult respiratory distress syndrome: Plea for rescue therapy of the alveolar epithelium
48. The risk of myocardial infarction associated with inhaled beta-adrenoceptor agonists
49. Hypokalemia after pediatric albuterol overdose: A case series
50. Bronchoconstriction induced by ipratropium bromide in asthma: Relation to bromide ion
51. Arterial blood levels of fluorocarbons in asthmatic patients
52. Ventilation-perfusion distributions in the adult respiratory distress syndrome
53. Redistribution of pulmonary blood flow induced by end expiratory pressure and dopamine infusion in acute respiratory failure
54. Distributions of Ventilation-perfusion in acute respiratory failure
55. Vasomotor regulation of the pulmonary circulation
56. A multicenter registry of patients with acute respiratory distress syndrome. Physiology and outcome
57. Cardiopulmonary parameters and prognosis after severe multiple trauma
58. Pulmonary hypertension in severe acute respiratory failure
59. Pulmonary vascular tone improves pulmonary gas exchange in the adult respiratory distress syndrome
60. Hydralazine does not inhibit canine hypoxic pulmonary vasoconstriction
61. Primary pulmonary hypertension. An analysis of 28 cases and a review of literature
62. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards
63. Effects of sodium nitroprusside on cardiovascular function and pulmonary shunt in canine oleic acid edema
64. Liposomal prostaglandin E1 in acute respiratory distress syndrome: A controlled, randomised, double blind, multicenter clinical trial
65. The effects of vasodilation with prostacyclin on oxygen delivery and uptake in critically ill patients
66. Relationship between oxygen uptake and oxygen delivery in septic patients: Effects of prostacyclin versus dobutamine
67. Prostaglandin E1 in the adult respiratory distress syndrome. Benefit for pulmonary hypertension and cost for pulmonary gas exchange
68. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome
69. Prostacyclin and right ventricular function in patients with pulmonary hypertension associated with ARDS
70. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: Effect of pulmonary capillary pressure and Ventilation-perfusion distributions
71. Effects of inhaled versus intravenous vasodilators in experimental pulmonary hypertension
72. Vasodilators in mechanical ventilated patients
73. The L-Arginine-nitric oxide pathway
74. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor
75. Inhibition of platelet aggregation by inhaled nitric oxide in patients with acute respiratory distress syndrome
76. Effect of inhaled NO on pulmonary function following sepsis in a swine model
77. The effect of inhaled NO on pulmonary ventilation-perfusion matching following smoke inhalation injury
78. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange
79. Inhaled nitric oxide reduces pulmonary transvascular albumin flux in patients with acute lung injury
80. Inhaled nitric oxide prevents pulmonary endothelial dysfunction after mesenteric ischemia-reperfusion
81. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: Results of a randomised phase II trial. Inhaled nitric oxide in ARDS Study Group
82. Inhalation of nitric oxide in acute lung injury. Preliminary results of a European multicenter study
83. Inhaled nitric oxide variably improves oxygenation and pulmonary hypertension in patients with acute respiratory distress syndrome
84. Inhaled nitric oxide versus conventional therapy: Effects on oxygenation in ARDS
85. Inhaled nitric oxide for the adult respiratory distress syndrome
86. Inhaled nitric oxide in acute respiratory distress syndrome: Pilot randomized controlled study
87. Positive end expiratory pressure and response to inhaled nitric oxide: Changing nonresponders to responders
88. Physiologic determinants of the response to inhaled nitric oxide in patients with acute respiratory distress syndrome
89. Factors influencing cardiopulmonary effects of inhaled nitric oxide in acute respiratory failure
90. Long term inhalation with low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome
91. Prolonged inhalation of low concentrations of nitric oxide in patients with severe adult respiratory distress syndrome. Effects on pulmonary hemodynamics and oxygenation
92. Time course and dose response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with acute respiratory distress syndrome
93. Inhaled nitric oxide in acute respiratory failure: Dose-response curves
94. Inhaled vasodilation therapy in acute lung injury: First do NO harm
95. The incidence and pathogenesis of cardiopulmonary deterioration after abrupt withdrawal of inhaled nitric oxide
96. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure
97. Inhaled nitric oxide-induced rebound pulmonary hypertension: Role for endothelin-1
98. Inhaled nitric oxide partially reverses hypoxic vasoconstriction in the dog
99. A new side effect of inhaled nitric oxide in neonates and infants with pulmonary hypertension: Functional impairment of the neutrophil respiratory burst
100. Prostacyclin PGI2: New aspects of and old substance in the treatment of critically ill patients
101. Cardiovascular and pulmonary effects of aerosolized prostacyclin administration in revere respiratory failure using a ventilator nebulization system
102. Continuous intraarterial measurement of oxygenation during aerosolized Prostacyclin administration
103. Aerosolized prostacyclin and inhaled nitric oxide in septic shock: Different effects on splachnic oxygenation
104. Direct comparison on inhaler of nitric oxide and aerosolized Prostacyclin in acute respiratory distress syndrome
105. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome
106. Effects of aerosolized prostacyclin and inhaled nitric oxide on experimental hypoxic pulmonary hypertension
107. Efficacy of inhaled prostanoids in experimental hypoxic pulmonary hypertension
108. Inhaled prostaglandin E1 for the treatment of acute lung injury
109. Nebulized prostacyclin in acute respiratory distress syndrome: Impact of primary (pulmonary injury) and secondary (extrapulmonary injury) disease on gas exchange response
110. Inhalation of Prostacyclin (PGI2) for 8 hours does not produce signs of acute pulmonary toxicity in healthy lambs
111. Identification of patients with acute lung injury. Predictors of mortality
112. Improved survival of patients with acute respiratory distress syndrome (ARDS): 1983-1993]
113. Acute lung injury in the medical ICU: Comorbid conditions, age, etiology, and hospital outcome
114. Thirty years of clinical trials in acute respiratory distress syndrome
115. Inhaled drug delivery in mechanically ventilated patients
116. Surface active materials from dog lung: Composition and physiological correlations
117. Surfactant in adult respiratory distress syndrome
118. Pulmonary perspective: A proposed nomenclature for pulmonary surfactant associated proteins
119. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome
120. Evidence of lung surfactant abnormality in respiratory failure. Study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol
121. Alterations of the endogenous surfactant system in septic adult rats
122. Characteristics of pulmonary surfactant in adult respiratory distress syndrome associated with trauma and shock
123. Abnormalities in lung elastic properties and surfactant function in adult respiratory distress syndrome
124. Surfactant abnormalities in patients with respiratory failure after multiple trauma
125. Effect of a Protective-Ventilation Strategy on Mortality in the Acute Respiratory Distress Syndrome
126. The acute respiratory distress syndrome
127. Effect of mechanical ventilation on inflammatory mediators in patients with acute respiratory distress syndrome: A randomized controlled trial
128. Surfactant replacement therapy
129. Artificial surfactant for therapy in hydrocarbon-induced lung injury
130. Intratracheal surfactant administration restores gas exchange in experimental adult respiratory distress syndrome associated with viral pneumonia
131. Bronchoscopic surfactant administration in patients with severe respiratory distress syndrome
132. Mitigation of endotoxin-induced acute lung injury in ventilated rabbits by surfactant and inhaled nitric oxide
133. Respiratory distress and surfactant inhibition following vagotomy in rabbits
134. Altered surfactant function and metabolism in rabbits with acute lung injury
135. Aerosolized surfactant improves pulmonary function in endotoxin-induced lung injury
136. Ultrasonic nebulization for efficient delivery of surfactant in a model of acute lung injury
137. Differential impact of Ultrasonic nebulized versus instilled on ventilation perfusion mismatch (VA/Q) surfactant in a model of acute lung injury
138. Ultrasonic nebulized in comparison with instilled surfactant treatment of preterm lambs
139. Evaluations of exogenous surfactant treatment strategies in an adult model of acute lung injury
140. Aerosolized surfactant treatment of preterm lambs
141. Aerosolized versus instilled exogenous surfactant in a nonuniform pattern of lung injury
142. Lung function and surfactant distribution in saline-lavaged sheep given instilled vs nebulized surfactant
143. Safety and potential efficacy of an aerosolized surfactant in human induced adult respiratory distress syndrome
144. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome
145. Effects of ventilation strategies on the efficacy of exogenous surfactant therapy in a rabbit model of acute lung injury
146. Effects of surfactant distribution and ventilation strategies on the efficacy of exogenous surfactant
147. Exogenous surfactant and positive end expiratory pressure in the treatment of endotoxin-induced lung injury
148. Aerosolized antimicrobials: Another look
149. Efficacy of aerosolized tobramycin in patients with cystic fibrosis
150. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis
151. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis
152. Intravenous or inhaled or pentamidine for treating Pneumocystis carinii pneumonia in AIDS
153. Dry powder versus intravenous and nebulized gentamicin cystic fibrosis and bronchiectasis. A pilot study
154. Deposition of amphotericin B aerosols in pulmonary aspergilloma
155. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Aerosolized Tobramycin Study Group
156. Aerosol polymyxin and pneumonia in seriously ill patients
157. Nebulizer choice for inhaled colistin treatment in cystic fibrosis
158. Inhaled gentamicin reduces airway neutrophil activity and mucus secretion in bronchiectasis
159. Aerosolized antibiotics in mechanically ventilated patients delivery and response
160. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis
161. Safety of aerosol tobramycin administration for 3 months to patients with cystic fibrosis
162. A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation
163. Effect of tonicity of nebulised colistin on chest tightness and pulmonary function in adults with cystic fibrosis
164. Nebulized colistin causes chest tightness in adults with cystic fibrosis
165. Theoretical validation of the respiratory benefits of helium-oxygen mixtures
166. Normal lung: Ventilation
167. Breathing heliox during mechanical ventilation: Effects in patients with chronic obstructive pulmonary disease abstract
168. Helium-oxygen mixtures in intubated with status asthmaticus and respiratory acidosis
169. Inhaled helium-oxygen revisited: Effect of inhaled helium-oxygen during the treatment of status asthmaticus in children
170. Heliox improves pulsus paradoxus and peak expiratory flow in nonintubated patients with severe asthma
171. Oxygenation in status asthmaticus improves during ventilation with helium-oxygen
172. Effects of helium-oxygen on intrinsic positive end-expiratory pressure in intubated and mechanically ventilated patients with severe chronic obstructive pulmonary disease
173. Safety and efficacy of heliox as a treatment for upper airway obstruction due to radiation-induced laryngeal dysfunction
174. Management of severe tracheal obstruction with helium/oxygen and laryngeal mask airway
175. Heliox delivery with noninvasive positive pressure ventilation: A laboratory study
176. Noninvasive ventilation with helium-oxygen in acute exacerbations of chronic obstructive pulmonary disease
177. Beneficial effects of helium:oxygen versus air: Oxygen noninvasive pressure support in patients with decompensated chronic obstructive pulmonary disease
178. Improvement in aerosol delivery with helium-oxygen mixtures during mechanical ventilation
179. Effect of nitric oxide, perfluorocarbon, and heliox on minute volume measurement and ventilator volumes delivered
180. Calibration of seven ICU ventilators for mechanical ventilation with helium-oxygen mixtures
181. Effectiveness of budesonide aerosol in ventilator-dependent premature babies: A preliminary report
182. Trial of beclomethasone dipropionate by meter-dose inhaler in ventilator-dependent neonates less than 1500 grams
183. Controlled short term trial of fluticasone propionate in ventilator-dependent patients with COPD